Abstract
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Wang X, Zhang K, Xiong D. Review paperToll-like receptor 4 polymorphisms and susceptibility to multiple autoimmune diseases: evidence based on pooled analysis. Central European Journal of Immunology. 2013;38(3):380-387. doi:10.5114/ceji.2013.37757. APA Wang, X., Zhang, K., & Xiong, D. (2013). Review paperToll-like receptor 4 polymorphisms and susceptibility to multiple autoimmune diseases: evidence based on pooled analysis. Central European Journal of Immunology, 38(3), 380-387. https://doi.org/10.5114/ceji.2013.37757 Chicago Wang, Xiao-qin, Kui Zhang, and Ding Xiong. 2013. "Review paperToll-like receptor 4 polymorphisms and susceptibility to multiple autoimmune diseases: evidence based on pooled analysis". Central European Journal of Immunology 38 (3): 380-387. doi:10.5114/ceji.2013.37757. Harvard Wang, X., Zhang, K., and Xiong, D. (2013). Review paperToll-like receptor 4 polymorphisms and susceptibility to multiple autoimmune diseases: evidence based on pooled analysis. Central European Journal of Immunology, 38(3), pp.380-387. https://doi.org/10.5114/ceji.2013.37757 MLA Wang, Xiao-qin et al. "Review paperToll-like receptor 4 polymorphisms and susceptibility to multiple autoimmune diseases: evidence based on pooled analysis." Central European Journal of Immunology, vol. 38, no. 3, 2013, pp. 380-387. doi:10.5114/ceji.2013.37757. Vancouver Wang X, Zhang K, Xiong D. Review paperToll-like receptor 4 polymorphisms and susceptibility to multiple autoimmune diseases: evidence based on pooled analysis. Central European Journal of Immunology. 2013;38(3):380-387. doi:10.5114/ceji.2013.37757.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
